Cargando…
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
SIMPLE SUMMARY: Oncolytic Herpes simplex virus-1 (HSV-1) offers the dual potential of both lytic tumor-specific cell killing and inducing anti-tumor immune responses. The HSV-1 genome can be altered to enhance both components and this may be applicable for the treatment of a broad range of cancers....
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760226/ https://www.ncbi.nlm.nih.gov/pubmed/33255871 http://dx.doi.org/10.3390/cancers12123514 |